BriaCell Raises $30 Million Through Public Offering of Units and Listed Warrants

BriaCell Therapeutics ( (TSE:BCT) ) has provided an update.

BriaCell Therapeutics has priced a best-efforts public offering of 5,366,726 units, each comprising one common share or pre-funded warrant and one warrant, at $5.59 per unit for expected gross proceeds of approximately $30 million before fees and expenses. The warrants, exercisable at $6.93 per share for five years, have been approved for listing on the Nasdaq Capital Market under the symbol BCTXL starting January 14, 2026, with the offering slated to close on January 15, 2026, subject to customary conditions; BriaCell plans to use the net proceeds to support working capital, general corporate purposes and advancement of its business objectives, reinforcing its funding base as it progresses its immunotherapy pipeline.

The most recent analyst rating on (TSE:BCT) stock is a Sell with a C$9.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.

Spark’s Take on TSE:BCT Stock

According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.

The score is driven primarily by weak financial performance (pre-revenue, expanding losses, and heavy cash burn despite no debt), reinforced by bearish technicals (price below key moving averages and negative MACD). Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.

To see Spark’s full report on TSE:BCT stock, click here.

More about BriaCell Therapeutics

BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care, with its shares listed on Nasdaq and the Toronto Stock Exchange.

Average Trading Volume: 6,128

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$18.88M

Learn more about BCT stock on TipRanks’ Stock Analysis page.